President Donald J. Trump’s 2025 initiative on drug prices Trump pharma aims to reduce U.S. prescription drug costs by requiring pharmaceutical companies to offer prices no higher than those in Europe and other developed nations. This strategy, announced in July 2025, uses executive action and trade policy to challenge current pricing practices and protect American patients and taxpayers.
Key Measures to Lower Drug Costs
The plan demands pharmaceutical manufacturers provide their most-favored-nation (MFN) prices—the lowest prices offered in developed countries—to all Medicaid patients in the United States. Companies must also commit not to offer better prices abroad than those in the U.S., preventing price discrimination that disadvantages American consumers.
Additionally, the government encourages manufacturers to bypass intermediaries by selling medicines directly to patients at prices no higher than Europe’s best. This direct-to-patient approach aims to reduce costs inflated by middlemen, improving affordability.
Leveraging Trade Policy and Enforcement
The administration plans to use trade policy to support manufacturers in raising prices internationally only if additional revenues are reinvested into lowering U.S. drug prices. If companies resist these demands, the government will employ all available tools to counteract abusive pricing practices, signaling a firm stance against pharmaceutical price gouging.
Letters outlining these conditions were sent to 18 major drugmakers, including Pfizer, Johnson & Johnson, Merck, and Novartis, emphasizing the seriousness of the administration’s efforts to secure the best drug prices in the world for Americans.